Literature DB >> 2691247

Frameshifting in the synthesis of Escherichia coli polypeptide chain release factor two on eukaryotic ribosomes.

J M Williams1, B C Donly, C M Brown, F M Adamski, C N Trotman, W P Tate.   

Abstract

A translational frameshift is necessary in the synthesis of Escherichia coli release factor 2 (RF-2) to bypass an in-frame termination codon within the coding sequence. The nucleotide sequence preceding the in-phase stop codon within RF-2 mRNA is complementary to the 3' anti-(Shine-Dalgarno sequence) region found in prokaryotic 16S rRNA and Weiss et al. (1988) have concluded that this pairing triggers the frameshift event. In vitro production of RNA coding for RF-2, suitable for translation on eukaryotic ribosomes, has enabled testing of whether eukaryotic ribosomes can frameshift at this sequence. The 18S rRNA of eukaryotic ribosomes does not contain the 3' anti-(Shine-Dalgarno sequence) region. The prokaryotic RF-2 gene and the gene for the other release factor, RF-1, which does not contain an in-frame stop codon, were subcloned into transcription vectors such that the RNA transcripts produced in vitro would resemble a typical eukaryotic mRNA. These RF-1 and RF-2 RNAs both synthesized a major product of Mr approximately 45,000 when translated in vitro within reticulocyte lysate; the size expected for full length RF-1 and RF-2 molecules. The RF-2 product was immunoprecipitated by RF-2-specific antibodies, including those to regions of the protein encoded in the mRNA downstream from the frameshift site. The putative premature termination product, an oligopeptide of 25 amino acids, was not detected, but a chemically synthesized derivative was shown to be very unstable within the translation system. Although it was not possible therefore to calculate an absolute efficiency of frameshifting, the relative efficiency of the translation of RF-2 RNA was estimated to be 10-20% of that of RF-1 RNA in the reticulocyte system. This was similar to the relative synthesis of the two proteins in a plasmid-DNA-directed prokaryotic transcription/translation system. These results show that in vitro on eukaryotic ribosomes where the Shine-Dalgarno-type interaction is not possible, high efficiency frameshifting around the in-phase stop codon in the RF-2 mRNA can still occur.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2691247     DOI: 10.1111/j.1432-1033.1989.tb15237.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  PGC-1alpha/beta upregulation is associated with improved oxidative phosphorylation in cells harboring nonsense mtDNA mutations.

Authors:  Sarika Srivastava; John N Barrett; Carlos T Moraes
Journal:  Hum Mol Genet       Date:  2007-03-06       Impact factor: 6.150

2.  Competition between frameshifting, termination and suppression at the frameshift site in the Escherichia coli release factor-2 mRNA.

Authors:  F M Adamski; B C Donly; W P Tate
Journal:  Nucleic Acids Res       Date:  1993-11-11       Impact factor: 16.971

3.  Frameshift autoregulation in the gene for Escherichia coli release factor 2: partly functional mutants result in frameshift enhancement.

Authors:  B C Donly; C D Edgar; F M Adamski; W P Tate
Journal:  Nucleic Acids Res       Date:  1990-11-25       Impact factor: 16.971

4.  Titration and conditional knockdown of the prfB gene in Escherichia coli: effects on growth and overproduction of the recombinant mammalian selenoprotein thioredoxin reductase.

Authors:  Olle Rengby; Elias S J Arnér
Journal:  Appl Environ Microbiol       Date:  2006-11-03       Impact factor: 4.792

5.  Special peptidyl-tRNA molecules can promote translational frameshifting without slippage.

Authors:  A Vimaladithan; P J Farabaugh
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

6.  A novel programed frameshift expresses the POL3 gene of retrotransposon Ty3 of yeast: frameshifting without tRNA slippage.

Authors:  P J Farabaugh; H Zhao; A Vimaladithan
Journal:  Cell       Date:  1993-07-16       Impact factor: 41.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.